Anti-vascular endothelial growth factor (anti-VEGF) agents have revolutionized the management of retinal vascular disorders characterized by pathological neovascularization or abnormal vascular permeability (Andreoli and Miller, 2007); hence, they have emerged as the first-line therapies for conditions such as diabetic macular edema (DME) and macular edema (ME) secondary to retinal vein occlusion (RVO). Here, VEGFA is linked to retinal vascular disorder.